In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular lymphoma. The EPCORE FL-1 trial results show a 79% progression-free ...

Epkinly plus R2 significantly improved PFS and response rates in relapsed/refractory follicular lymphoma, reducing disease progression risk by 79%. The Epkinly regimen achieved a 95% objective ...

Mosunetuzumab (Lunsumio) is a first-in-class bispecific antibody that last year received accelerated approval for relapsed or refractory follicular lymphoma. At the recent American Society of ...

Please provide your email address to receive an email when new articles are posted on . Most patients in the high-risk study population had some response to treatment. All high-grade treatment-related ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...

How Does Lunsumio Work for FL? Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on lymphoma ...

WORCESTER, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies ...

In follicular lymphoma patients treated with rituximab plus epcoritamab, the 1-year progression-free survival rate was 97% and the 1-year overall survival rate was 100%. Treatment with rituximab plus ...

Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...

This two-arm prospective phase III open-label trial randomly assigns (1:1) participants with low–tumor burden FL who wish to pursue active management to rituximab versus mosunetuzumab (Fig 1), ...